{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-090055","form_type":"8-K","ticker":"JSPR","cik":"0001788028","company_name":"Jasper Therapeutics, Inc.","filed_at":"2026-08-14T20:07:42+00:00","discovered_at":"2026-08-14T20:14:04.613970+00:00","generated_at":"2026-08-14T20:14:24.939188+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Jasper Therapeutics Q2 2026 net loss $2.8M; closes Kira acquisition, $132M PIPE","bullets":["Q2 2026 net loss $2.8M ($0.10/share); cash $7.3M at June 30, 2026.","Closed all-stock acquisition of Kira Pharmaceuticals in July 2026.","Raised $132M gross proceeds in PIPE co-led by Affinity and Ikarian.","KP-104 Phase 2 interim data expected Q4 2026; briquilimab pre-BLA meeting Q1 2027.","R&D expense $5.1M, G&A $4.1M for Q2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-090055","json":"https://secwatch.observer/filing/0001213900-26-090055.json","markdown":"https://secwatch.observer/filing/0001213900-26-090055.md","text":"https://secwatch.observer/filing/0001213900-26-090055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1788028/000121390026090055/0001213900-26-090055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1788028/000121390026090055/ea0302049-8k_jasper.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-14T20:14:24.939188+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}